Thermo Fisher Scientific Daclizumab Chimeric Recombinant Mouse Monoclonal Antibody (Daclizumab)

Applications

Tested Dilution

Publications

Flow Cytometry (Flow)

Assay-dependent

-

Inhibition Assays (IA)

Assay-dependent

-

Product Specifications

Species Reactivity

Cynomolgus monkey, Human, Rhesus monkey

Host/Isotype

Mouse / IgG1, kappa

Expression System

HEK293 cells

Class

Recombinant Monoclonal

Type

Antibody

Clone

Daclizumab

Immunogen

Cultured T-cells derived from a patient with Mycosis fungoides.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Protein A

Storage buffer

PBS

Contains

0.02% ProClin 300

Storage conditions

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Shipping conditions

Wet ice

Product Specific Information

Binds to p55 chain of IL2R on human T cells, Tac antigen, which is expressed on T cells activated by mitogens, soluble antigens, and alloantigens but not on resting T cells, thymocytes, B cells, monocytes, activated B cells, leukemic T cell blasts from patients with acute lymphoblastic leukemia, and long-term T cell lines.

Target Information

Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody. On 22 April 2008, Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection in de novo allogeneic renal transplantation and used concomitantly with an immunosuppressive regimen like cyclosporine and corticosteroids in patients who are not immunized, for commercial reasons and confirmed that this decision was not related to any safety concerns associated with the use of Zenapax (daclizumab) 2. Regardless of the withdrawal of Zenapax, Biogen and Abbvie`s Zinbryta (daclizumab), as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by the FDA in 2016.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.